HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon

2006

Article référencé dans le Web of Science WOS:000239984700005

Vergne Laurence, Diagbouga S., Kouanfack C., Aghokeng Fobang Avelin, Butel Christelle, Laurent Christian, Noumssi N., Tardy M., Sawadogo A., Drabo J., Hien H., Zekeng L., Delaporte Eric, Peeters Martine

Antiviral Therapy, 2006, 11 (5), p. 575-579 ISSN 1359-6535

We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n=1], M41L+T69S [n=1]), four to non-NRTIs (NNRTIs; V106A/V [n=1] and V108I [n=3]) and two to protease inhibitors (Pls; L33F [n=2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to Pls (M46I/L [n=2], L33F [n=1]), three to NRTIs (T69N/T [n=1], M184V [n=1], A62V [n=1]) and two to NNRTIs (P236L [n=1], V108I [n=1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes.

Entomologie médicale / Parasitologie / Virologie [052]

BURKINA FASO ; CAMEROUN

Fonds IRD [F B010056496]

fdi:010056496